A behind-the-scenes program that has quietly held down Medicare drug-plan premiums is being switched off a year ahead of schedule, and the effect could show up in what some retirees pay in 2027. Federal officials are ending the Part D Premium Stabilization Demonstration on December 31, 2026, rather than letting it run through 2027 as expected. The change is technical, but its consequence is not: a benchmark figure that determines who pays nothing for a drug plan is projected to drop sharply, and some enrollees who currently owe no premium could owe one next year.
The subsidy program being switched off early
The demonstration was created to cushion standalone Part D premiums after a major overhaul of the drug benefit. When the Inflation Reduction Act redesigned Part D, adding protections like an annual out-of-pocket cap, insurers faced pressure that could have pushed premiums up. The stabilization program limited how much standalone drug-plan premiums could rise year to year, effectively subsidizing part of the cost to keep plans affordable while the new design settled in.
That cushion was widely expected to continue through 2027. Instead, the Centers for Medicare & Medicaid Services is letting it expire at the end of 2026. Ending it a year early removes the buffer that has been muting premium increases across standalone Part D plans, which is why the timing has drawn attention from beneficiary advocates.
The benchmark number that decides who pays nothing
The most consequential piece is a figure most enrollees never see: the benchmark premium. Medicare uses this benchmark to set the level of assistance for low-income beneficiaries and to determine which plans a person receiving the Extra Help subsidy can enroll in for a zero-dollar premium. When the benchmark is high, more plans fall at or below it, and more people pay nothing.
That benchmark is projected to fall from $36.17 in 2026 to $13.25 in 2027. A lower benchmark means fewer plans qualify as zero-premium options for subsidized enrollees. The practical result is that some people who have paid nothing for their drug coverage could be asked to pay a premium in 2027 to keep the same plan, or would need to switch to a different plan that still lands under the reduced benchmark.
Free retirement updates: Miss an enrollment or claim deadline and it may be gone. Our free Retirement Shield newsletter keeps readers ahead of the ones that matter. Get the free newsletter.
A dispute over how much premiums will actually rise
How large the hit will be is genuinely contested. CMS Administrator Mehmet Oz has said most enrollees will see an increase of less than $10 a month, or in some cases a lower premium, framing the end of the demonstration as a modest adjustment. The agency’s position is that the market has stabilized enough that the extra cushion is no longer needed.
Advocacy groups see it differently. Families USA and other consumer advocates dispute the reassurance, arguing that the sharp drop in the benchmark and the loss of the stabilization payments will push premiums higher than the official estimate suggests, particularly for lower-income enrollees who are most sensitive to even small increases. The gap between those two characterizations is why the final 2027 premiums, once plans are posted, will be the real test.
What stays protected under the drug-benefit redesign
It is important to separate the demonstration ending from the broader drug-benefit reforms, which are not being rolled back. The core Inflation Reduction Act changes to Part D remain in place. Those include the annual cap on out-of-pocket prescription spending, the $35 monthly limit on covered insulin, and no-cost recommended vaccines. Ending the premium cushion changes what some people pay in premiums; it does not undo the protections that limit what they pay at the pharmacy counter.
That distinction matters for retirees weighing whether their coverage is getting worse. The safeguards that cap catastrophic drug costs continue. What is changing is the premium math on the front end, driven by the loss of the stabilization payments and the lower benchmark that flows from them.
Why the fall enrollment window is the moment to act
The change lands squarely inside the annual shopping season, which makes the fall the time to pay attention. Standalone Part D and Medicare Advantage drug plans reset their premiums and formularies each year, and the Medicare fall Annual Enrollment Period is when enrollees can compare and switch. Anyone who has paid nothing for a drug plan should verify, when 2027 plan details post, whether that plan still carries a zero premium or has moved above the reduced benchmark.
Comparing plans through the official Medicare Part D tools, rather than assuming last year’s plan carries over unchanged, is the defense against an unexpected premium. For a subsidized enrollee, the difference between staying put and switching to a plan still under the benchmark could be the difference between paying zero and paying a monthly premium for the first time. The program change is set; the individual response happens during open enrollment.
This article was produced with the assistance of artificial intelligence and reviewed by The Financial Wire editorial team.
More Financial Reading
- What really happens to your joint savings account when you die?
- Bank statements: how long to keep them and when to toss them
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
